C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI. | MicrobiomeTrials← Back to trialsNCT07250724
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-03-01Est. Completion: 2026-10-15
Enrollment target: 60 participants Locations- Emory University Hospital, Atlanta, Georgia, United States
- Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, United States
- Mayo Clinic, Minnesota, Rochester, Minnesota, United States
- University of Wisconsin-Madison, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection RecurrenceClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceCDIC. Diff InfectionRecurrent Clostridium Difficile InfectionC.Difficile DiarrheaDiarrhea Infectious
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (…
Huntsville, United StatesEst. completion Jun 2027
The gut microbiota plays a crucial role in human health, influencing metabolism, immunity, and pathogen resistance. Rese…
Rome, ItalyEst. completion Mar 10, 2027
Clostridium Difficile Infection
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …
Multiple LocationsEst. completion Aug 22, 2028